Skip to main content

Table 1 Regional demographic and disease-related summaries of the participants at baseline a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

  North America Western Europe Australia/South Africa Japan Asia Eastern Europe/Russia South America/Mexico Total sample
N (%) 1,884 (40.1) 981 (20.9) 237 (5.1) 435 (9.3) 339 (7.2) 408 (8.7) 410 (8.7) 4,694 (100)
Age, yr (mean ± SD) 75.1 ± 8.3EE,AS,JP,AU,WE 71.9 ± 7.8SA,JP 72.9 ± 7.4SA,EE,NA 73.4 ± 7.6SA,NA 72.1 ± 7.6SA,NA 70.7 ± 7.8SA,AU,NA 75.4 ± 7.7EE,AS,JP,AU,WE 73.6 ± 8.1
Female sex, n (%) 986 (52.3)SA,EE,JP 503 (51.3) SA,EE,JP 128 (54.0)SA 276 (63.5)WE,NA 191 (56.3) 255 (62.5)WE,NA 279 (68.1)AU,WE,NA 2,618 (55.8)
Height, cm (mean ± SD) 166.5 ± 10.7SA,EE,AS,JP 166.1 ± 9.8SA,EE,AS,JP 166.8 ± 9.7SA,EE,AS,JP 154.6 ± 8.9SA,EE,AS,AU,WE,NA 158.2 ± 8.6EE,JP,AU,WE,NA 163.4 ± 9.1SA,AS,JP,AU,WE,NA 160.0 ± 9.1EE,JP,AU,WE,NA 163.9 ± 10.7
Weight, kg (mean ± SD) 73.2 ± 15.7SA,EE,AS,JP,WE 70.2 ± 12.7SA,AS,JP,NA 70.7 ± 13.1SA,AS,JP 53.1 ± 10.0SA,EE,AS,AU,WE,NA 58.5 ± 9.7SA,EE,JP,AU,WE,NA 68.8 ± 12.6AS,JP,NA 66.6 ± 12.5AS,JP,AU,WE,NA 68.6 ± 15.0
Body mass index, kg/m2 (mean ± SD) 26.3 ± 4.7AS,JP,WE 25.4 ± 3.8AS,JP,NA 25.4 ± 4.1AS,JP 22.1 ± 3.1SA,EE,AS,AU,WE,NA 23.3 ± 3.1SA,EE,JP,AU,WE,NA 25.4 ± 3.8AS,JP 26.0 ± 4.3AS,JP 25.4 ± 4.4
Years of education (mean ± SD) 14.1 ± 3.3SA,EE,AS,JP,AU,WE 11.2 ± 4.2SA,EE,AS,NA 12.1 ± 3.5SA,AS,WE,NA 11.7 ± 2.7SA,AS,NA 9.5 ± 4.7EE,JP,AU,WE,NA 11.9 ± 3.8SA,AS,WE,NA 8.9 ± 4.5EE,JP,AU,WE,NA 12.2 ± 4.1
APOE ε4 genotype carriers, n (%) 1,086 (63.2)SA,EE,AS,JP 494 (63.3)SA,EE,AS,JP 149 (63.7)SA 220 (51.9)WE,NA 93 (48.4)WE,NA 191 (51.1)WE,NA 189 (49.5)AU,WE,NA 2,422 (59.0)
Years since symptom onset (mean ± SD) 4.8 ± 2.6EE,AS,JP 4.6 ± 2.5EE,JP 4.7 ± 2.8EE,JP 3.7 ± 2.3SA,AS,AU,WE,NA 4.2 ± 2.4JP,NA 3.9 ± 2.2SA,AU,WE,NA 4.5 ± 2.4EE,JP 4.5 ± 2.5
Years since diagnosis (mean ± SD) 2.5 ± 2.1EE,AS,JP,AU,WE 2.1 ± 1.8EE,JP,NA 2.0 ± 1.8EE,NA 1.7 ± 1.5SA,WE,NA 2.0 ± 1.9SA,EE,NA 1.5 ± 1.5SA,AS,AU,WE,NA 2.4 ± 1.9EE,AS,JP 2.2 ± 1.9
Proportion taking any anti-AD medication, n (%) 1,677 (89.0) EE,AS,AU 902 (92.0)SA,EE,AS,AU 172 (72.6)JP,WE,NA 389 (89.4)AS,AU 274 (80.8)WE,NA 302 (74.0)JP,WE,NA 342 (83.4)WE 4,058 (86.5)
Proportion taking dual anti-AD therapy, n (%) 894 (47.5)SA,EE,AS,JP,AU,WE 147 (15.0)SA,AS,JP,AU,NA 16 (6.8)SA,JP,WE,NA 3 (0.7)SA,EE,AS,AU,WE,NA 21 (6.2)SA,EE,JP,WE,NA 58 (14.2)SA,AS,JP,NA 117 (28.5)EE,AS,JP,AU,WE,NA 1,256 (26.8)
Proportion enrolling with spouse study partner, n (%) 1,318 (70.4)SA,EE,AS 719 (73.7)SA,EE,AS 178 (75.7)SA,EE,AS 279 (64.6)SA,EE,AS 172 (50.9)JP,AU,WE,NA 163 (40.1)JP,AU,WE,NA 174 (42.7)JP,AU,WE,NA 3,003 (64.4)
Proportion enrolling with adult child study partner, n (%) 374 (20.0) 192 (19.7) 36 (15.3) 116 (26.9) 136 (40.2) 203 (49.9) 162 (39.7) 1,219 (26.1)
Proportion enrolling with other study partner, n (%) 179 (9.6) 64 (6.6) 21 (8.9) 37 (8.6) 30 (8.9) 41 (10.1) 72 (17.7) 444 (9.5)
  1. aSA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa; WE = P < 0.01 vs Western Europe; NA = P < 0.01 vs North America; AD = Alzheimer’s disease; APOE = Apolipoprotein E; Dual therapy = treatment with a cholinesterase inhibitor and memantine; SD = Standard deviation.